CervoMed (CRVO) Net Equity Issued and Repurchased (2010 - 2026)

CervoMed (CRVO) posted Net Equity Issued and Repurchased of $4.7 million for Q3 2025, little changed sequentially from $4.7 million in Q2 2025.

CervoMed (CRVO) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends

CervoMed has reported Net Equity Issued and Repurchased for 10 years, with the latest figure at $4.7 million in Q3 2025.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $4.7 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $9.4 million (up 1060.49% YoY) and the FY2025 annual result came in at $4.6 million, changed N/A from the prior year.
Net Equity Issued and Repurchased steadied at $4.7 million in Q3 2025 per CRVO's latest filing, from $4.7 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $31.1 million in Q1 2021 and troughed at $810000.0 in Q3 2023.
A 3-year average of $10.3 million and a median of $4.7 million in 2025 frame the typical range for Net Equity Issued and Repurchased.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	CervoMed	26.64 Mn	26.64 Mn	-	4.70 Mn

Download Data